Clinical trials: Traveler's Diarrhea
Travelers Diarrhea
Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia
The study proposed here will determine the frequency and etiology of diarrhea in Australian adult tourists traveling to Southeast Asia, including Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand…
- Trial name
- AusTD (NCT06363890)
- Testing
- TAQMan Array Card
- Where
- Australia
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Diarrhea, Travelers Diarrhea
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
This is a randomized, double-blind, placebo-controlled study to investigate a single daily dose of Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli…
- Conditions
- Diarrhea, Travelers Diarrhea, Infectious Diarrhea
- Trial name
- NCT05933525
- Testing
- Travelan
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Immuron Ltd.
Diarrhea Travelers, Antibiotic Resistant Infection
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among…
- Trial name
- NCT03535272
- Testing
- Bismuth subsalicylate
- Where
- United States
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Diarrhoea;Acute, Diarrhea Travelers
Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
The purpose of this study is to compare a single dose of rifaximin with loperamide to the current standard approach of single dose azithromycin with loperamide for the treatment of acute watery traveler's diarrhea (TD).
- Trial name
- TrEAT_TD2 (NCT05677282)
- Testing
- Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
- Where
- 4 sites in Djibouti, Honduras and 2 more
- Volunteers
- 150 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Travelers Diarrhea
G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
The goal of this interventional study is to learn about the intraluminal pharmacokinetics (PK) of the investigational drug LMN-401 in adult healthy volunteers with ileostomies.
- Trial name
- NCT06556940
- Testing
- LMN-401
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Travelers' Diarrhea, Functional Bowel Disorders
Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD
The purpose of this study is to develop evidence on the relative efficacy of 2 rifaximin chemoprophylaxis regimens for the prevention of Travelers' Diarrhea (TD) in a deployed setting.
- Conditions
- Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
- Trial name
- NCT02498301
- Testing
- Rifaximin
- Where
- 6 sites in United States, Kenya
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Traveler's Diarrhea
Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
This will be a double-blind comparative study, performed in pediatric subjects (Age 6-11) traveling to developing regions with a known high incidence of traveler's diarrhea.
- Trial name
- NCT04026984
- Testing
- Rifamycin SV-MMX
- Volunteers
- 142 people
- Sponsor
- RedHill Biopharma Limited
Traveler's Diarrhea
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea.
- Trial name
- NCT04027894
- Testing
- Rifamycin SV MMX
- Volunteers
- 142 people
- Sponsor
- RedHill Biopharma Limited
Prevention of Travelers' Diarrhea
LT Vaccine Patch Self-Administration Study
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered…
- Trial name
- NCT00565461
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Prevention of Travelers' Diarrhea
Traveler's Diarrhea (TD) Automated Process
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
- Trial name
- NCT00751777
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Antibiotic Resistant Infection, Antibiotic Resistant Strain
ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas.
- Conditions
- Antibiotic Resistant Infection, Antibiotic Resistant Strain, Traveler's Diarrhea
- Trial name
- NCT03866291
- Testing
- No intervention, observational
- Where
- Sweden
- Volunteers
- 305 people
- Sponsor
- Lund University
Travelers' Diarrhea
A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
This study compared safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea.
- Trial name
- NCT02920242
- Testing
- Rifaximin (Sandoz GmbH) tablet, Rifaximin (Xifaxan)
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Sandoz
Traveler's Diarrhea
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.
- Trial name
- ERASE (NCT01208922)
- Testing
- Rifamycin SV-MMX®, Ciprofloxacin
- Where
- 19 sites in Ecuador, Guatemala and 1 more
- Volunteers
- 835 people
- Sponsor
- Dr. Falk Pharma GmbH
Traveler's Diarrhea
PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli
The APA12/PANTER study is a parallel 3-weeks intervention study. Subjects will be randomly assigned to one of two treatment groups; placebo or PTM202 (n=36 per group).
- Trial name
- APA12/PANTER (NCT03301103)
- Testing
- E. coli strain E1392-75-2A, PTM202
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Traveler's Diarrhea
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.
- Trial name
- NCT01142089
- Testing
- Rifamycin SV MMX
- Where
- 12 sites in Guatemala, Mexico
- Volunteers
- 264 people
- Sponsor
- Cosmo Technologies Ltd
Traveler's Diarrhea
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea
This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea.
- Trial name
- NCT02736539
- Testing
- CBS 2004 (galacto-oligosaccharides)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clasado Biosciences Ltd
Travelers' Diarrhea
Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17
This will be a strain and dose-finding study in which LSN03-016011/A ETEC will be administered at a starting inoculum of 5x108 cfu to 5 subjects to establish a human disease model.
- Trial name
- NCT00564577
- Testing
- CFA/I and CS17 challenge strain
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Travelers' Diarrhea
Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD
This is a Phase II, randomized, double-blind, placebo-controlled study designed to investigate whether hyperimmune bovine milk IgG products specific for CsbD and CS17, protect subjects against diarrhea upon challenge with a…
- Trial name
- BIgGII (NCT00524004)
- Testing
- Anti-CsbD Bovine IgG, Anti-CS17 Bovin IgG
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Travelers' Diarrhea
Dose-Finding Study of CS19 Expressing ETEC Challenge Strains
This will be a strain and dose-finding study in which CS19-ETEC strain WS0115A will be administered at a starting inoculum of 5 x 108 colony forming units (cfu) to 5 subjects as the initial step to establish a human disease…
- Trial name
- NCT00564863
- Testing
- CS19 expressing ETEC strain
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Travelers' Diarrhea
Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR 2.
- Trial name
- Rifaximin 600 (NCT00875875)
- Testing
- Rifaximin
- Where
- Mexico
- Sponsor
- The University of Texas Health Science Center, Houston